Cagrilintide
An amylin-receptor agonist being examined for appetite regulation and sustained weight-management support.
Laboratory and educational research purposes only.What is Cagrilintide?
Cagrilintide is a long-acting amylin analog, designed as a once-weekly injectable for obesity and metabolic disease management. Amylin is a peptide hormone co-secreted with insulin by pancreatic β-cells, regulating satiety, gastric emptying, and glucagon secretion. Cagrilintide is being developed by Novo Nordisk, often studied in combination with semaglutide (GLP-1 RA) for synergistic weight loss.
Mechanism(s) of Action
Amylin receptor agonist (calcitonin receptor + RAMP complexes): Promotes satiety by acting on the hypothalamus.
Delays gastric emptying: Slows nutrient absorption, enhancing fullness and reducing postprandial glucose spikes.
Suppresses glucagon secretion: Helps stabilize glucose control.
Acts on CNS appetite pathways: Reduces food cravings and energy intake.
Works synergistically with GLP-1 receptor agonists (GLP-1 RAs) for amplified effects on satiety and weight loss.
1. Promotes weight loss — reduces appetite and caloric intake.
2. Enhances satiety — increases fullness between meals.
3. Delays gastric emptying — slows digestion, reduces overeating.
4. Improves glucose control — suppresses inappropriate glucagon secretion.
5. Supports fat loss over lean mass loss — preserves muscle tissue while promoting fat reduction.
6. Synergy with GLP-1 RAs (e.g., semaglutide, liraglutide, tirzepatide, retatrutide) — provides greater weight loss than either alone.
7. Improved adherence — long half-life allows weekly dosing.
Summary:
Cagrilintide is a long-acting amylin analog that promotes weight loss, satiety, and glucose stability. By slowing gastric emptying and suppressing glucagon, it helps reduce food intake while preserving lean mass. It is particularly effective when combined with GLP-1 agonists like semaglutide, making it a promising therapy for obesity and metabolic disorders.